- $92.93m
- $92.31m
- CA$0.03m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 6.84 | ||
Price to Tang. Book | 6.84 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 3,554.95 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -61.77% | ||
Return on Equity | -47.77% | ||
Operating Margin | -32839.54% |
Financial Summary
Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | CA$m | n/a | 0 | 0.35 | 0.07 | 0.03 | n/a | n/a | n/a |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Zentek Ltd. is a Canada-based graphene technology company. The principal business of the Company is to develop opportunities in the graphene and related nano-materials industry based on its intellectual property, patents and unique Albany graphite. The Company is focused on the research, development, and commercialization of graphene-based products. The Company's technology helps filter and deactivate pathogens to reduce the risk of transmission. The Company is focused on commercializing ZenGUARD, which is a hydrophilic, water attracting coating that adsorbs bacteria and virus-laden aerosols and deactivates them, increasing public safety, and reducing the risk of transmission of COVID and other pathogens. The Company is developing a graphene-based fuel additive that can reduce greenhouse gas (GHG) emissions from diesel and bio-diesel fuels. The Company’s developments include Aptamers & Rapid Detection and Graphene-Oxide Synthesis & Graphene Synthesis.
Directors
- Francis Dube CHM
- Peter Wood PRE
- Gregory Fenton CEO
- Brian Bosse CFO
- James Jordan VOP
- Colin Van Der Kuur VRD
- Frank Klees IND
- Eric Wallman IND
- Last Annual
- March 31st, 2024
- Last Interim
- June 30th, 2024
- Incorporated
- July 29th, 2008
- Public Since
- December 22nd, 2010
- No. of Employees
- 25
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market
- Shares in Issue
- 101,229,977
![Blurred out image of a map](https://www.stockopedia.com/assets/conversion/images/maps_placeholder.jpg)
- Address
- 24 Corporate Ct, GUELPH, N1G 5G5
- Web
- https://www.zentek.com/
- Phone
- +1 7056180900
- Auditors
- BDO Canada LLP
Upcoming Events for ZTEK
Similar to ZTEK
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
As of Today at 24:17 UTC, shares in Zentek are trading at $0.95. This share price information is delayed by 15 minutes.
Shares in Zentek last closed at $0.95 and the price had moved by -32.14% over the past 365 days. In terms of relative price strength the Zentek share price has underperformed the S&P500 Index by -46.94% over the past year.
The overall consensus recommendation for Zentek is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreZentek does not currently pay a dividend.
Zentek does not currently pay a dividend.
Zentek does not currently pay a dividend.
To buy shares in Zentek you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.95, shares in Zentek had a market capitalisation of $92.93m.
Here are the trading details for Zentek:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ZTEK
Based on an overall assessment of its quality, value and momentum Zentek is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Zentek is $2.22. That is 133.8% above the last closing price of $0.95.
Analysts covering Zentek currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Zentek. Over the past six months, its share price has underperformed the S&P500 Index by -31.62%.
As of the last closing price of $0.95, shares in Zentek were trading -16.53% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Zentek PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.95.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Zentek's management team is headed by:
- Francis Dube - CHM
- Peter Wood - PRE
- Gregory Fenton - CEO
- Brian Bosse - CFO
- James Jordan - VOP
- Colin Van Der Kuur - VRD
- Frank Klees - IND
- Eric Wallman - IND